医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Simavita Updates on New Agreements, Pilots and Key Appointments

2015年03月23日 PM06:00
このエントリーをはてなブックマークに追加


 

SYDNEY

Simavita Limited (ASX:SVA)(TSX-V:SV)(“Simavita” or the “Company”), a global leader in the digital healthcare sector, is pleased to provide details of material of new agreements to supply its Smart Incontinence Management solution (SIM®) in Australia, updates on the progress of showcase sites in Canada and Sweden and the launch of significant pilot sites in the US, as well as announce two key executive appointments.

Highlights from a more detailed announcement are below.

Simavita expands the roll out of its transformational Smart Incontinence Management (SIM®) platform and executes further agreements with leading aged care providers

New agreements have been signed with key customers in Australia with McKenzie Group and Queensland Rehabilitation Services, and the roll out of SIM® into Australian customer, Arcare’s facilities is progressing, with 19 of 24 homes now using SIM®. It is anticipated that the minimum aggregate value of the agreements with the above customers will be around $800,000 AUD per annum.

“The importance of these groups to Simavita goes beyond a commercial arrangement. Each one is recognised as a leading aged care provider who is focused on the efficiencies and potential revenue uplift gained from implementing cutting edge technologies like SIM®. We are delighted to be working together,” said Philippa Lewis, CEO of Simavita.

Revenue is now being generated from the sale of SIM® on three continents, with significant pilot programs proceeding well in the US, Denmark, Canada and Sweden

In the US, Canada and Sweden, several aged care facilities are piloting the SIM® technology. Importantly, the Swedish pilot follows the earlier announcement that Simavita had signed Danish distributor, Abena A/S after completion of a successful trial in Denmark. Through a combination of direct sales and distribution agreements with Medline in the US and Abena in Denmark, revenues are now being realised in each of the key regions of Australia, the United States and Europe.

Key executive appointments made to drive sales in Australian and North American markets to drive SIM® sales

Simavita welcomes new key executives to the team.

Christopher Southerland joins Simavita as US Executive V.P. of Sales and Marketing responsible for overseeing SIM® sales and distribution activities in North America. Charles Cornish joins Simavita in the role of Director ANZ. Charles will lead the Company’s Marketing, Sales and Service Team.

The full announcement can be accessed via:
http://sva.live.irmau.com/IRM/Company/ShowPage.aspx/PDFs/1031-10000000/Simavitaprogressupdate

For further information, see our website (www.simavita.com) or contact the persons outlined below.

About Simavita

Simavita is a medical device company operating in the digital healthcare sector that has developed an innovative, world first solution for the management of urinary incontinence, with a focus on the elderly. The first product is the SIM™ platform technology which is an instrumented incontinence assessment application that provides evidence based incontinence management care plans to the residential aged care market.

About SIM

SIM™ is a wireless sensor technology that delivers evidence-based instrument incontinence data on individuals. SIM™ provides user friendly tools and software to assess the incontinence condition and to help plan better outcomes. SIM™ is used to detect, record and report incontinence events during a compulsory or recommended assessment period in residential aged care facilities to develop an evidence-based incontinence care plan.

Conducting assessments is mandatory in many countries and the incontinence assessment creates an influential element of care of each individual.

CONTACT

Company
Simavita Limited
Philippa Lewis, +61-2-8405-6381
Chief
Executive Officer
Thomas Howitt, +61-418-351-127
Chief
Financial Officer
Media and Investor Relations
Jane
Lowe, +61-411-117-774
jane.lowe@irdepartment.com.au

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease